Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14764449 | 0.85 | CSNK2A1 (0.44) | CSNK2A1HSD17B10NPC1USP2RAB9A | |
| SCHEMBL14764203 | 0.85 | MAPT (0.42) | HSD17B10NPC1USP2RAB9ASMN1; SMN2 | |
| SCHEMBL5240461 | 0.82 | CSNK2A1 (0.51) | CSNK2A1SMN1; SMN2KDM4EMAPTGAA | |
| SCHEMBL14764254 | 0.81 | KDM4E (0.48) | CSNK2A1KDM4EGAAMAPK1ALDH1A1 | |
| SCHEMBL16816730 | 0.79 | CSNK2A1 (0.49) | CSNK2A1HSD17B10NPC1USP2RAB9A | |
| SCHEMBL18994421 | 0.78 | MAPT (0.47) | CSNK2A1HSD17B10SMN1; SMN2KDM4EMAPT | |
| SCHEMBL2894087 | 0.78 | KDM4E (0.55) | CSNK2A1KDM4EMAPTGAAMAPK1 | |
| SCHEMBL14764675 | 0.78 | CYP1A2 (0.50) | CSNK2A1HSD17B10NPC1USP2RAB9A | |
| SCHEMBL3126227 | 0.78 | KDM1A (0.51) | CSNK2A1HSD17B10KDM4EMAPTGAA | |
| SCHEMBL15966562 | 0.78 | MAPT (0.44) | CSNK2A1HSD17B10NPC1USP2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190085007-A1 | 4-methylcatechol Derivatives and Uses Thereof | Thanares GmbH (DE) | 2019-03-21 | — | — | US | claimed |
| US-20160347782-A1 | 4-methylcatechol Derivatives and Uses Thereof | Thanares GmbH (DE) | 2016-12-01 | — | — | US | claimed |
| WO-2013034119-A1 | 4-METHYLCATECHOL DERIVATIVES UND USE THEREOF | Thanares GmbH (DE) | 2013-03-14 | — | — | WO | claimed |
| US-20190085007-A1 | 4-methylcatechol Derivatives and Uses Thereof | Thanares GmbH (DE) | 2019-03-21 | — | — | US | disclosed |
| US-20160347782-A1 | 4-methylcatechol Derivatives and Uses Thereof | Thanares GmbH (DE) | 2016-12-01 | — | — | US | disclosed |
| WO-2013034119-A1 | 4-METHYLCATECHOL DERIVATIVES UND USE THEREOF | Thanares GmbH (DE) | 2013-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190085007-A1 | 4-methylcatechol Derivatives and Uses Thereof | ST3GAL3, GALE, DPP4 | CSNK2A1 4055/4885HSD17B10 468/4885NPC1 509/4885 |
| US-20160347782-A1 | 4-methylcatechol Derivatives and Uses Thereof | ST3GAL3, GALE, DPP4 | CSNK2A1 4055/4885HSD17B10 468/4885NPC1 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.